

Hans Wildiers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1912065/publications.pdf>

Version: 2024-02-01

237
papers

18,066
citations

23567

58
h-index

15732

125
g-index

250
all docs

250
docs citations

250
times ranked

19760
citing authors

#	ARTICLE	IF	CITATIONS
1	Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. <i>Acta Oncologica</i> , 2022, 61, 22-29.	1.8	17
2	Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial. <i>Annals of Oncology</i> , 2022, 33, 299-309.	1.2	19
3	Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 293-301.	2.5	7
4	Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial. <i>Journal of Geriatric Oncology</i> , 2022, 13, 582-593.	1.0	4
5	The role of vitamin D in breast cancer risk and progression. <i>Endocrine-Related Cancer</i> , 2022, 29, R33-R55.	3.1	34
6	Abstract P2-08-23: Early intratumoral changes after a single dose of anti-PD-1 treatment in patients with early breast cancer (BC). <i>Cancer Research</i> , 2022, 82, P2-08-23-P2-08-23.	0.9	0
7	Elevated CA 15.3 in Newly Diagnosed Breast Cancer: A Retrospective Study. <i>Clinical Breast Cancer</i> , 2022, 22, 579-587.	2.4	4
8	Geriatric assessment in the management of older patients with cancer – A systematic review (update). <i>Journal of Geriatric Oncology</i> , 2022, 13, 761-777.	1.0	67
9	Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. <i>Annals of Oncology</i> , 2022, 33, 769-785.	1.2	37
10	Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. <i>Breast</i> , 2022, 64, 100-111.	2.2	5
11	Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets. <i>Clinical Chemistry</i> , 2022, 68, 1164-1176.	3.2	6
12	Updated SIOG COVID-19 working group recommendations on COVID-19 vaccination among older adults with cancer. <i>Journal of Geriatric Oncology</i> , 2022, , .	1.0	2
13	Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 146-153.	6.3	31
14	Unplanned hospitalizations in older patients with cancer: Occurrence and predictive factors. <i>Journal of Geriatric Oncology</i> , 2021, 12, 368-374.	1.0	14
15	How to use dialysis wisely in cancer patients?. <i>Journal of Onco-Nephrology</i> , 2021, 5, 79-86.	0.6	1
16	Scalp cooling in breast cancer patients treated with docetaxel – cyclophosphamide: patient- and nurse-reported results. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 715-722.	2.5	4
17	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021, 124, 842-854.	6.4	5
18	Retrospective Analysis of the Clinical Presentation, Treatment and Outcome of Angiosarcoma in a Sarcoma Referral Center. <i>Oncology Research and Treatment</i> , 2021, 44, 322-332.	1.2	2

#	ARTICLE	IF	CITATIONS
19	Real-time symptom management in the context of a remote symptom-monitoring system: prospective process evaluation and cross-sectional survey to explore clinical relevance. <i>Supportive Care in Cancer</i> , 2021, 29, 3401-3408.	2.2	8
20	Identifying frailty in clinically fit patients diagnosed with hematological malignancies using a simple clinico-biological screening tool: The HEMA-4 study. <i>Journal of Geriatric Oncology</i> , 2021, 12, 902-908.	1.0	7
21	Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2 ⁻ early breast cancer. <i>Modern Pathology</i> , 2021, 34, 1297-1309.	5.5	5
22	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , 2021, 7, 162-172.	1.8	38
23	Cancer and Aging: Two Tightly Interconnected Biological Processes. <i>Cancers</i> , 2021, 13, 1400.	3.7	83
24	Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 609.	7.1	15
25	A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. <i>Nature Medicine</i> , 2021, 27, 820-832.	30.7	330
26	Immune-related adverse events after a single dose of pembrolizumab. <i>European Journal of Cancer</i> , 2021, 148, 92-94.	2.8	1
27	Blood Immunosenescence Signatures Reflecting Age, Frailty and Tumor Immune Infiltrate in Patients with Early Luminal Breast Cancer. <i>Cancers</i> , 2021, 13, 2185.	3.7	2
28	Targeted Therapies in Older Adults With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 2128-2137.	1.6	7
29	Cause of death for patients with breast cancer: discordance between death certificates and medical files, and impact on survival estimates. <i>Archives of Public Health</i> , 2021, 79, 111.	2.4	5
30	The SIOG COVID-19 working group recommendations on the rollout of COVID-19 vaccines among older adults with cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 848-850.	1.0	11
31	Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover). <i>Clinical Cancer Research</i> , 2021, 27, 4983-4993.	7.0	9
32	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	9.4	79
33	Intra-Arterial Therapies for Liver Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1868-1882.	2.0	1
34	Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). <i>Lancet Oncology</i> , The, 2021, 22, e327-e340.	10.7	121
35	Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape. <i>ESMO Open</i> , 2021, 6, 100204.	4.5	30
36	Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study. <i>ESMO Open</i> , 2021, 6, 100207.	4.5	3

#	ARTICLE	IF	CITATIONS
37	Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5818-5827.	7.0	14
38	Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3. <i>ESMO Open</i> , 2021, 6, 100203.	4.5	8
39	Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 128.	5.2	2
40	Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 357-372.	2.5	2
41	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	3.7	12
42	Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey. <i>ESMO Open</i> , 2021, 6, 100219.	4.5	4
43	Efficacy and safety of first-line veliparib and carboplatin+paclitaxel in patients with HER2+ advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. <i>European Journal of Cancer</i> , 2021, 154, 35-45.	2.8	10
44	Solitary pituitary metastasis from HER2-positive breast cancer treated with stereotactic radiotherapy – a case report. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100081.	0.1	0
45	Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1041-1048.	2.5	1
46	Priorities for the global advancement of care for older adults with cancer: an update of the International Society of Geriatric Oncology Priorities Initiative. <i>Lancet Oncology</i> , The, 2021, 22, e29-e36.	10.7	71
47	Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 417-428.	2.5	20
48	Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 183-194.	2.5	14
49	POLRMT as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients. <i>Pharmaceutics</i> , 2021, 13, 1942.	4.5	7
50	948...Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC. , 2021, 9, A997-A997.		2
51	Clinical Trial Design for Older Cancer Patients. , 2021, , 1042-1048.		0
52	Targeted therapy for breast cancer in older patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 380-388.	1.0	9
53	Risk-reducing mastectomy in BRCA carriers: survival is not the issue. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 251-252.	2.5	5
54	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120

#	ARTICLE	IF	CITATIONS
55	Underrepresentation of vulnerable older patients with cancer in phase II and III oncology registration trials: A case-control study. <i>Journal of Geriatric Oncology</i> , 2020, 11, 320-326.	1.0	16
56	Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. <i>European Journal of Cancer</i> , 2020, 125, 69-82.	2.8	36
57	Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. <i>ESMO Open</i> , 2020, 5, e000947.	4.5	63
58	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With 2 HER2-Directed Regimens: Phase III NALA Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3138-3149.	1.6	355
59	Anticancer drugs are not well tolerated in all older patients with cancer. <i>The Lancet Healthy Longevity</i> , 2020, 1, e43-e47.	4.6	31
60	Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1190-1198.	1.0	60
61	Breast Cancer Detection and Treatment Monitoring Using a Noninvasive Prenatal Testing Platform: Utility in Pregnant and Nonpregnant Populations. <i>Clinical Chemistry</i> , 2020, 66, 1414-1423.	3.2	9
62	Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , 2020, 5, e000853.	4.5	29
63	Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1269-1282.	10.7	207
64	Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical features in invasive micropapillary breast carcinoma with long-term outcomes. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 985-998.	2.5	9
65	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. <i>Nature Communications</i> , 2020, 11, 6335.	12.8	46
66	The prognostic value of patient-reported Health-Related Quality of Life and Geriatric Assessment in predicting early death in 6769 older (≥70 years) patients with different cancer tumors. <i>Journal of Geriatric Oncology</i> , 2020, 11, 926-936.	1.0	7
67	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
68	The added value of geriatric assessment in evaluating a patient's Health-Related Quality of Life: A study in ≥70-year-old early-stage invasive breast cancer patients. <i>European Journal of Cancer Care</i> , 2020, 29, e13278.	1.5	6
69	Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in <i>BRCA1/2</i> : A Review of Secondary Prevention Guidelines. <i>Journal of Oncology</i> , 2020, 2020, 1-13.	1.3	20
70	Behavior of metastatic breast cancer according to subtype. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 115-125.	2.5	32
71	Effects of a mindfulness-based intervention on cancer-related cognitive impairment: Results of a randomized controlled functional magnetic resonance imaging pilot study. <i>Cancer</i> , 2020, 126, 4246-4255.	4.1	32
72	A Systematic Review of Estimating Breast Cancer Recurrence at the Population Level With Administrative Data. <i>Journal of the National Cancer Institute</i> , 2020, 112, 979-988.	6.3	17

#	ARTICLE	IF	CITATIONS
73	Computerised scoring protocol for identification and quantification of different immune cell populations in breast tumour regions by the use of QuPath software. <i>Histopathology</i> , 2020, 77, 79-91.	2.9	33
74	Sequential intra-arterial infusion of 90Y-resin microspheres and mitomycin C in chemo refractory liver metastatic breast cancer patients: a single centre pilot study. <i>Radiology and Oncology</i> , 2020, 54, 33-39.	1.7	5
75	Clinical Trial Design for Older Cancer Patients. , 2020, , 1-7.		0
76	Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies. <i>Acta Clinica Belgica</i> , 2019, 74, 169-179.	1.2	5
77	Survival outcomes of the NeoALTTO study (BIG 1â€“06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. <i>European Journal of Cancer</i> , 2019, 118, 169-177.	2.8	51
78	A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 121-133.	2.5	4
79	Ageâ€“dependent brain volume and neuropsychological changes after chemotherapy in breast cancer patients. <i>Human Brain Mapping</i> , 2019, 40, 4994-5010.	3.6	25
80	Decentralization of Next-Generation RNA Sequencing-Based MammaPrintÂ® and BlueprintÂ® Kit at University Hospitals Leuven and Curie Institute Paris. <i>Translational Oncology</i> , 2019, 12, 1557-1565.	3.7	6
81	HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology. <i>Journal of Geriatric Oncology</i> , 2019, 10, 1003-1013.	1.0	40
82	Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 607-615.	2.5	10
83	Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 597-605.	2.5	7
84	Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 699-708.	2.5	22
85	Health related quality of life in older patients with solid tumors and prognostic factors for decline. <i>Journal of Geriatric Oncology</i> , 2019, 10, 895-903.	1.0	20
86	Cancer events in Belgian nursing home residents: An EORTC prospective cohort study. <i>Journal of Geriatric Oncology</i> , 2019, 10, 805-810.	1.0	4
87	Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. <i>Oncologist</i> , 2019, 24, 165-171.	3.7	23
88	Bone metastases and age are associated with earlier dose reductions in metastatic clear-cell renal cell carcinoma patients treated with angiogenesis inhibitors. <i>Acta Clinica Belgica</i> , 2019, 74, 414-423.	1.2	1
89	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	6.2	711
90	Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast. <i>European Journal of Surgical Oncology</i> , 2019, 45, 550-559.	1.0	14

#	ARTICLE	IF	CITATIONS
91	Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 55-63.	2.5	3
92	SIOG guidelines- essential for good clinical practice in geriatric oncology. <i>Journal of Geriatric Oncology</i> , 2019, 10, 196-198.	1.0	14
93	Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, 47-57.	2.4	8
94	Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery. <i>Quality of Life Research</i> , 2019, 28, 663-676.	3.1	23
95	Medical Management of Advanced Disease. , 2019, , 219-228.		0
96	Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial. <i>Clinical Cancer Research</i> , 2018, 24, 2312-2318.	7.0	51
97	Breast cancer subtype and survival by parity and time since last birth. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 481-487.	2.5	6
98	Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. <i>Lancet Oncology</i> , The, 2018, 19, 323-336.	10.7	94
99	The influence of coping strategies on subsequent well-being in older patients with cancer: A comparison with 2 control groups. <i>Psycho-Oncology</i> , 2018, 27, 864-870.	2.3	10
100	Low levels of intra-tumoural T cells in breast cancer identify clinically frail patients with shorter disease-specific survival. <i>Journal of Geriatric Oncology</i> , 2018, 9, 606-612.	1.0	5
101	A nursing intervention aimed at reducing symptom burden during chemotherapy (CHEMO-SUPPORT): A mixed-methods study of the patient experience. <i>European Journal of Oncology Nursing</i> , 2018, 34, 35-41.	2.1	18
102	Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. <i>Acta Clinica Belgica</i> , 2018, 73, 100-109.	1.2	42
103	Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>Supportive Care in Cancer</i> , 2018, 26, 869-878.	2.2	39
104	Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 115-126.	10.7	333
105	The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged ≥ 70 with early stage invasive breast cancer. <i>Journal of Geriatric Oncology</i> , 2018, 9, 152-162.	1.0	16
106	Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS). <i>Journal of Geriatric Oncology</i> , 2018, 9, 93-101.	1.0	14
107	Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 189-196.	2.5	7
108	What Every Oncologist Should Know About Geriatric Assessment for Older Patients With Cancer: Young International Society of Geriatric Oncology Position Paper. <i>Journal of Oncology Practice</i> , 2018, 14, 85-94.	2.5	120

#	ARTICLE	IF	CITATIONS
109	UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer. <i>European Journal of Cancer</i> , 2018, 103, 184-194.	2.8	6
110	The prognostic value of 3 commonly measured blood parameters and geriatric assessment to predict overall survival in addition to clinical information in older patients with cancer. <i>Cancer</i> , 2018, 124, 3764-3775.	4.1	11
111	The added value of geriatric screening and assessment for predicting overall survival in older patients with cancer. <i>Cancer</i> , 2018, 124, 3753-3763.	4.1	31
112	Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Portal Hypertension-Induced Refractory Ascites Due to Metastatic Carcinomatous Liver Disease. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1713-1716.	0.5	7
113	Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy. <i>BMC Cancer</i> , 2018, 18, 1014.	2.6	12
114	Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer. <i>Clinical Drug Investigation</i> , 2018, 38, 1071-1075.	2.2	4
115	A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 109.	5.0	48
116	Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 131-141.	2.5	12
117	Systematic development of CHEMO-SUPPORT, a nursing intervention to support adult patients with cancer in dealing with chemotherapy-related symptoms at home. <i>BMC Nursing</i> , 2018, 17, 28.	2.5	9
118	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018, 50, 968-978.	21.4	184
119	Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium. <i>Annals of Oncology</i> , 2018, 29, 1987-1994.	1.2	52
120	Cognitive Impairment, Hypoalbuminemia, High CRP Level and Past History of Gastro-Intestinal Ulcer: 4 Markers of Frailty Which Identify Older Patients with Malignant Hemopathies Who Shouldn't Benefit from Chemotherapy. <i>Blood</i> , 2018, 132, 4756-4756.	1.4	0
121	Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty. <i>Breast Cancer Research</i> , 2017, 19, 20.	5.0	32
122	Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 743-754.	10.7	372
123	MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2 ⁺ Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5218-5224.	7.0	492
124	Functional decline in older patients with cancer receiving chemotherapy: A multicenter prospective study. <i>Journal of Geriatric Oncology</i> , 2017, 8, 196-205.	1.0	99
125	Omitting radiation therapy in women with triple-negative breast cancer leads to worse breast cancer-specific survival. <i>Breast</i> , 2017, 32, 18-25.	2.2	16
126	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	27.8	1,099

#	ARTICLE	IF	CITATIONS
127	Geriatric Assessment and Functional Decline in Older Patients with Lung Cancer. <i>Lung</i> , 2017, 195, 619-626.	3.3	39
128	Postoperative complications in individuals aged 70 and over undergoing elective surgery for colorectal cancer. <i>Colorectal Disease</i> , 2017, 19, O329-O338.	1.4	39
129	Value of geriatric screening and assessment in predicting postoperative complications in patients older than 70 years undergoing surgery for colorectal cancer. <i>Journal of Geriatric Oncology</i> , 2017, 8, 320-327.	1.0	54
130	Use of a symptom diary during chemotherapy: A mixed-methods evaluation of the patient perspective. <i>European Journal of Oncology Nursing</i> , 2017, 31, 37-45.	2.1	16
131	A Case of Severe Acute Cardiac Failure on Sunitinib After Left-Sided Thoracal Radiation Therapy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e155-e158.	1.9	2
132	Relevance of Geriatric Assessment in Older Patients With Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, e221-e229.	2.3	22
133	Body mass index and breast cancer survival: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2017, 46, 1814-1822.	1.9	45
134	The utilization of formal and informal home care by older patients with cancer: a Belgian cohort study with two control groups. <i>BMC Health Services Research</i> , 2017, 17, 644.	2.2	2
135	The footprint of the ageing stroma in older patients with breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 78.	5.0	22
136	Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. <i>Breast Cancer Research</i> , 2017, 19, 119.	5.0	43
137	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	4.5	82
138	Implementation of uHear, a iOS-based application to screen for hearing loss - in older patients with cancer undergoing a comprehensive geriatric assessment. <i>Journal of Geriatric Oncology</i> , 2016, 7, 126-133.	1.0	17
139	The impact of frailty on postoperative outcomes in individuals aged 65 and over undergoing elective surgery for colorectal cancer: A systematic review. <i>Journal of Geriatric Oncology</i> , 2016, 7, 479-491.	1.0	164
140	Dealing with chemotherapy-related symptoms at home: a qualitative study in adult patients with cancer. <i>European Journal of Cancer Care</i> , 2016, 25, 79-92.	1.5	41
141	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. <i>Human Molecular Genetics</i> , 2016, 25, 3863-3876.	2.9	33
142	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	9.4	157
143	Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. <i>International Journal of Cancer</i> , 2016, 139, 2336-2342.	5.1	69
144	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	12.8	78

#	ARTICLE	IF	CITATIONS
145	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. <i>British Journal of Cancer</i> , 2016, 115, 1471-1478.	6.4	45
146	A Belgian survey on geriatric assessment in oncology focusing on large-scale implementation and related barriers and facilitators. <i>Journal of Nutrition, Health and Aging</i> , 2016, 20, 60-70.	3.3	26
147	Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 603-607.	2.5	6
148	Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force. <i>Cancer Treatment Reviews</i> , 2016, 43, 19-26.	7.7	51
149	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016, 48, 374-386.	21.4	125
150	The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. <i>Oncotarget</i> , 2016, 7, 29977-29988.	1.8	39
151	Prediction of Poor Outcome in Older Patients Receiving Chemotherapy for Malignant Lymphoma: A New Frailty Scoring. <i>Blood</i> , 2016, 128, 2353-2353.	1.4	0
152	The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. <i>European Journal of Cancer</i> , 2015, 51, 2808-2819.	2.8	105
153	A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. <i>BMC Cancer</i> , 2015, 15, 978.	2.6	6
154	Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). <i>Annals of Oncology</i> , 2015, 26, 873-879.	1.2	151
155	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	428
156	Different adjuvant chemotherapy regimens in older breast cancer patients?. <i>Annals of Oncology</i> , 2015, 26, 613-615.	1.2	2
157	Withdrawal of hormone replacement therapy might affect multigene signature results in early luminal breast cancer. <i>Annals of Oncology</i> , 2015, 26, 437-438.	1.2	3
158	Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. <i>Breast</i> , 2015, 24, 182-190.	2.2	44
159	Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). <i>Annals of Oncology</i> , 2015, 26, 1677-1684.	1.2	68
160	Implementation of geriatric assessment-based recommendations in older patients with cancer: A multicentre prospective study. <i>Journal of Geriatric Oncology</i> , 2015, 6, 401-410.	1.0	47
161	Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients. <i>Drugs and Aging</i> , 2015, 32, 821-834.	2.7	12
162	Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 67-76.	2.5	61

#	ARTICLE	IF	CITATIONS
163	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv219.	6.3	99
164	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 285-298.	2.9	38
165	Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. <i>Annals of Oncology</i> , 2015, 26, 288-300.	1.2	607
166	Biological ageing and frailty markers in breast cancer patients. <i>Aging</i> , 2015, 7, 319-333.	3.1	45
167	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. <i>Oncotarget</i> , 2015, 6, 7390-7407.	1.8	15
168	Circulating MicroRNAs as Easy-to-Measure Aging Biomarkers in Older Breast Cancer Patients: Correlation with Chronological Age but Not with Fitness/Frailty Status. <i>PLoS ONE</i> , 2014, 9, e110644.	2.5	49
169	Performance of Two Geriatric Screening Tools in Older Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 19-26.	1.6	308
170	Multicenter implementation of geriatric assessment in Belgian patients with cancer: A survey on treating physicians' general experiences and expectations. <i>Journal of Geriatric Oncology</i> , 2014, 5, 431-438.	1.0	26
171	How to Implement a Geriatric Assessment in Your Clinical Practice. <i>Oncologist</i> , 2014, 19, 1056-1068.	3.7	68
172	Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 689-699.	10.7	595
173	Evaluating the physiological reserves of older patients with cancer: The value of potential biomarkers of aging?. <i>Journal of Geriatric Oncology</i> , 2014, 5, 204-218.	1.0	74
174	Adverse events with everolimus in BOLERO-2. <i>Annals of Oncology</i> , 2014, 25, 1861.	1.2	1
175	Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 557-570.	2.5	23
176	Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens. <i>European Journal of Cancer</i> , 2014, 50, 2925-2931.	2.8	14
177	ADJUVANT CHEMOTHERAPY IN OLDER BREAST CANCER PATIENTS: HOW TO DECIDE. <i>Journal of Geriatric Oncology</i> , 2014, 5, S3.	1.0	1
178	International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2595-2603.	1.6	1,380
179	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014, 5, 4999.	12.8	105
180	Prognostic implications of lobular breast cancer histology: New insights from a single hospital cross-sectional study and SEER data. <i>Breast</i> , 2014, 23, 371-377.	2.2	10

#	ARTICLE	IF	CITATIONS
181	Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors. <i>BMC Cancer</i> , 2014, 14, 201.	2.6	20
182	Reply to T. To et al.. <i>Journal of Geriatric Oncology</i> , 2014, 5, 221-222.	1.0	0
183	Characteristics and effectiveness of complex nursing interventions aimed at reducing symptom burden in adult patients treated with chemotherapy: A systematic review of randomized controlled trials. <i>International Journal of Nursing Studies</i> , 2014, 51, 495-510.	5.6	46
184	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. <i>Breast Cancer Research</i> , 2014, 16, R51.	5.0	14
185	Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). <i>Annals of Oncology</i> , 2013, 24, 1513-1525.	1.2	57
186	The influence of clinical assessment (including age) and geriatric assessment on treatment decisions in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2013, 4, 235-241.	1.0	72
187	Triple negative breast cancer: Clinical characteristics in the different histological subtypes. <i>Breast</i> , 2013, 22, 761-766.	2.2	47
188	Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. <i>Annals of Oncology</i> , 2013, 24, 1306-1312.	1.2	285
189	Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. <i>Annals of Oncology</i> , 2013, 24, 350-355.	1.2	35
190	Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers. <i>Annals of Oncology</i> , 2013, 24, 1847-1852.	1.2	34
191	End Points and Trial Design in Geriatric Oncology Research: A Joint European Organisation for Research and Treatment of Cancerâ€“Alliance for Clinical Trials in Oncologyâ€“International Society of Geriatric Oncology Position Article. <i>Journal of Clinical Oncology</i> , 2013, 31, 3711-3718.	1.6	267
192	Circulating CCL5 Levels in Patients with Breast Cancer: Is There a Correlation with Lymph Node Metastasis?. <i>ISRN Immunology</i> , 2013, 2013, 1-5.	0.7	8
193	The impact of patient-related factors on the occurrence of febrile neutropenia in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin, and cyclofosfamide (FEC) x6 or FEC x3 followed by docetaxel (D) x3.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1078-1078.	1.6	0
194	Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. <i>Annals of Oncology</i> , 2012, 23, 2578-2584.	1.2	46
195	Triple-negative breast cancer in the older population. <i>Annals of Oncology</i> , 2012, 23, vi52-vi55.	1.2	50
196	Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). <i>Lancet Oncology</i> , The, 2012, 13, e148-e160.	10.7	505
197	Comprehensive geriatric assessment (CGA) in older oncological patients: Why and how?. <i>Journal of Geriatric Oncology</i> , 2012, 3, 174-176.	1.0	25
198	The EORTC Cancer in the Elderly Task Force, a Protostar for EORTC's future. <i>European Journal of Cancer</i> , Supplement, 2012, 10, 34-38.	2.2	8

#	ARTICLE	IF	CITATIONS
199	The influence of age plus standard clinical approach with or without comprehensive geriatric assessment (CGA) on treatment decisions in older cancer patients: Final results.. Journal of Clinical Oncology, 2012, 30, 9035-9035.	1.6	0
200	The impact of genetic variability on severe toxicity of (neo-) adjuvant chemotherapy in breast cancer patients receiving 5-fluorouracil, epirubicin, and cyclofosfamide (FEC).. Journal of Clinical Oncology, 2012, 30, 1020-1020.	1.6	0
201	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	6.3	596
202	Main priorities for the development of geriatric oncology: A worldwide expert perspective. Journal of Geriatric Oncology, 2011, 2, 270-273.	1.0	41
203	Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients. Breast Cancer Research and Treatment, 2011, 128, 429-435.	2.5	26
204	Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Critical Reviews in Oncology/Hematology, 2011, 77, 221-240.	4.4	121
205	Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. Annals of Oncology, 2011, 22, 588-594.	1.2	25
206	Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment, 2010, 123, 463-469.	2.5	44
207	A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis. Annals of Oncology, 2010, 21, 419-423.	1.2	16
208	Qualitative Assessment of the Progesterone Receptor and HER2 Improves the Nottingham Prognostic Index Up to 5 Years After Breast Cancer Diagnosis. Journal of Clinical Oncology, 2010, 28, 4129-4134.	1.6	51
209	Questionnaires and instruments for a multidimensional assessment of the older cancer patient: What clinicians need to know?. European Journal of Cancer, 2010, 46, 1019-1025.	2.8	72
210	EORTC elderly task force position paper: Approach to the older cancer patient. European Journal of Cancer, 2010, 46, 1502-1513.	2.8	300
211	Taxanes and anthracyclines in early breast cancer: which first?. Lancet Oncology, The, 2010, 11, 219-220.	10.7	20
212	Relationship Between Age and Axillary Lymph Node Involvement in Women With Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2931-2937.	1.6	72
213	Atropine, Hyoscine Butylbromide, or Scopolamine Are Equally Effective for the Treatment of Death Rattle in Terminal Care. Journal of Pain and Symptom Management, 2009, 38, 124-133.	1.2	90
214	Delivery of adjuvant sequential dose-dense FECâ€“Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment, 2009, 114, 103-112.	2.5	26
215	Administration of 24-hour intravenous infusions of trabectedin every 3 weeks in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps. Journal of Clinical Oncology, 2009, 27, e13530-e13530.	1.6	0
216	Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. Critical Reviews in Oncology/Hematology, 2008, 65, 156-163.	4.4	447

#	ARTICLE	IF	CITATIONS
217	Intra-hepatic Mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 135-142.	2.5	18
218	A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 133-138.	4.4	17
219	Strain Rate Imaging Detects Early Cardiac Effects of Pegylated Liposomal Doxorubicin as Adjuvant Therapy in Elderly Patients with Breast Cancer. <i>Journal of the American Society of Echocardiography</i> , 2008, 21, 1283-1289.	2.8	165
220	Challenges in treating older cancer patients: breast cancer. <i>Annals of Oncology</i> , 2008, 19, vii99-vii103.	1.2	10
221	Does Estrogen Receptorâ€“Negative/Progesterone Receptorâ€“Positive Breast Carcinoma Exist?. <i>Journal of Clinical Oncology</i> , 2008, 26, 335-336.	1.6	91
222	Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. <i>Annals of Oncology</i> , 2007, 18, 1314-1321.	1.2	132
223	Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). <i>Annals of Oncology</i> , 2007, 18, 64-69.	1.2	121
224	International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. <i>European Journal of Cancer</i> , 2007, 43, 14-34.	2.8	224
225	Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. <i>Lancet Oncology</i> , The, 2007, 8, 1101-1115.	10.7	313
226	International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patientsâ€“An Analysis of the Medical Literature. <i>Journal of Clinical Oncology</i> , 2007, 25, 1832-1843.	1.6	210
227	Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 127-133.	2.5	19
228	Adjuvant chemotherapy in elderly patients with breast cancer: where are we?. <i>Current Opinion in Oncology</i> , 2005, 17, 566-572.	2.4	13
229	Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. <i>Breast Cancer Research and Treatment</i> , 2005, 91, 81-87.	2.5	56
230	Taxanes in elderly breast cancer patients. <i>Cancer Treatment Reviews</i> , 2004, 30, 333-342.	7.7	56
231	Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study. <i>Anti-Cancer Drugs</i> , 2004, 15, 341-346.	1.4	36
232	Immuno affinity purification combined with mass spectrometry detection for the monitoring of VEGF isoforms in patient tumor tissue. <i>Journal of Separation Science</i> , 2003, 26, 619-623.	2.5	11
233	Effect of anti-vascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. <i>British Journal of Cancer</i> , 2003, 88, 1979-1986.	6.4	296
234	Pharmacology of Anticancer Drugs in the Elderly Population. <i>Clinical Pharmacokinetics</i> , 2003, 42, 1213-1242.	3.5	110

#	ARTICLE	IF	CITATIONS
235	Death Rattle. <i>Journal of Pain and Symptom Management</i> , 2002, 23, 310-317.	1.2	116
236	Melphalan availability in hypoxia-inducible factor-1 ^{+/+} and factor-1 ^{-/-} tumors is independent of tumor vessel density and correlates with melphalan erythrocyte transport. <i>International Journal of Cancer</i> , 2002, 99, 514-519.	5.1	15
237	The Combination of the CDK4/6 Inhibitor, Palbociclib, With the Vitamin D3 Analog, Inecalcitol, Has Potent In Vitro and In Vivo Anticancer Effects in Hormone-Sensitive Breast Cancer, But Has a More Limited Effect in Triple-Negative Breast Cancer. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	3